Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic Interaction of BI 409306 and Donepezil
NCT02635750Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2016
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of osoresnontrine in Alzheimer's disease (AD) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point and Maximum measured concentration of the analyte in plasma. Started Jan 2016; status: completed.
02
Drugs
osoresnontrine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02635750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02635750.